$TAK

TAKEDA PHARMACEUTICAL CO LTD

Takeda is a global research and development-driven biopharmaceutical company that discovers and delivers prescription medicines and other treatments for patients with rare and more prevalent diseases. Its core research areas are gastrointestinal and inflammation, neuroscience, and oncology, with additional businesses in plasma-derived therapies and vaccines. Commercial activities are organized around six areas: GI, Rare Diseases, PDT, Oncology, Vaccines and Neuroscience. Products include ENTYVIO for ulcerative colitis and Crohn’s disease, TAKHZYRO for hereditary angioedema, plasma-derived immunoglobulin and albumin therapies, and the QDENGA dengue vaccine. Takeda makes money by marketing prescription drugs and other treatments worldwide, and through its plasma-derived therapies and vaccine business. It conducts research and development internally and with external partners. The company has a presence in approximately 80 countries and regions and approximately 47,000 employees worldwide. Its global head office is in Tokyo, Japan.

8
0
0
—
$2.1M
Bitetti Teresa Marie
0%
See all $TAK insider activity →
Low

Lanadelumab Reduces Pediatric HAE Attacks 95% in Real-World Analysis

Real-world data presented at the ACAAI 2026 meeting showed lanadelumab (Takhzyro) reduced HAE attacks by 95% in pediatric patients, according to a retrospective chart review. The FDA expanded its approval to children aged 2+ in 2023. Phase 3 SPRING study results also showed a 94.8% attack rate reduction. Takeda is the drug's manufacturer.

Belantamab Mafodotin Moves Into Lenalidomide-Refractory Myeloma in Updated NCCN Guidelines

The NCCN updated its guidelines to include GSK's belantamab mafodotin (Blenrep) plus bortezomib and dexamethasone as a category 1 recommendation for lenalidomide-refractory multiple myeloma. The update also includes two other belantamab triplets under 'Useful in Certain Circumstances' for patients with 3 or more prior therapies. The changes follow the drug's FDA approval in October 2025 and reflect its efficacy in clinical trials.

TAK sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 8 news stories mentioning TAK (TAKEDA PHARMACEUTICAL CO LTD). Coverage has skewed bullish: 8 bullish, 0 neutral, and 0 bearish.

Recent TAK coverage spans earnings, financial news and insider activity.

In the last 30 days, TAK insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($2.1M). The most active reporter was Bitetti Teresa Marie, President, OBU, with 1 filing.

What's driving TAK

AlphAI scores every news story that mentions TAK with an AI model for sentiment and relevance, and aggregates insider trades from TAKEDA PHARMACEUTICAL CO LTD's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $TAK

Score

Lanadelumab Reduces Pediatric HAE Attacks 95% in Real-World Analysis

Real-world data presented at the ACAAI 2026 meeting showed lanadelumab (Takhzyro) reduced HAE attacks by 95% in pediatric patients, according to a retrospective chart review. The FDA expanded its approval to children aged 2+ in 2023. Phase 3 SPRING study results also showed a 94.8% attack rate reduction. Takeda is the drug's manufacturer.

Belantamab Mafodotin Moves Into Lenalidomide-Refractory Myeloma in Updated NCCN Guidelines

The NCCN updated its guidelines to include GSK's belantamab mafodotin (Blenrep) plus bortezomib and dexamethasone as a category 1 recommendation for lenalidomide-refractory multiple myeloma. The update also includes two other belantamab triplets under 'Useful in Certain Circumstances' for patients with 3 or more prior therapies. The changes follow the drug's FDA approval in October 2025 and reflect its efficacy in clinical trials.

Key facts: TSE:4502 keeps guidance; launches ORZEYFUL; 3k roles cut

Takeda (4502) maintained full-year guidance, expecting a low-single-digit revenue decline at constant FX. The company raised revenue and core operating profit forecasts, launched ORZEYFUL for narcolepsy, and plans a U.S. launch. Takeda cut 3,000 roles, achieved procurement savings, and aims for ¥100B gross savings by FY2026. The FDA approved MIMRYLO for erythrocytosis, and accepted zasocitinib for priority review. ENTYVIO showed reduced UC complications in a study.

$TAKHighAI 8/10

Takeda FY2026 Q2 slides: new medicines set growth trajectory

Takeda Pharmaceutical (NYSE:TAK) reported FY2026 Q2 earnings, with core revenue at JPY 2,407.0 billion ($15.3 billion) and core operating profit at JPY 710.6 billion ($4.5 billion). The company highlighted growth from three new medicines: ORZEYFUL, MIMRYLO, and zasocitinib. Operating cash flow decreased 27.2% to JPY 431.9 billion, and free cash flow fell 38.0% to JPY 325.7 billion. Takeda maintained its annual dividend of 204 yen per share.

HighAI 8/10Earnings

TAKEDA PHARMACEUTICAL CO LTD (TAK): Financial results for H2 2026

TAKEDA PHARMACEUTICAL CO LTD (TAK) furnished an SEC Form 6-K — earnings release. Information furnished on this form: EXHIBIT Exhibit Number 1. (English Translation) Earnings Report (Kessan Tanshin) for the Six -month Period Ended September 30, 2026 99.1 Financial Appendix SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the regi

Related tickers